http://purl.org/np/RAuK2SpdSrihmtW-VW1AcZGZP1hr4oW30pnWBV-AEakLs#Head
http://purl.org/np/RAuK2SpdSrihmtW-VW1AcZGZP1hr4oW30pnWBV-AEakLs
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RAuK2SpdSrihmtW-VW1AcZGZP1hr4oW30pnWBV-AEakLs#assertion
http://purl.org/np/RAuK2SpdSrihmtW-VW1AcZGZP1hr4oW30pnWBV-AEakLs
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RAuK2SpdSrihmtW-VW1AcZGZP1hr4oW30pnWBV-AEakLs#provenance
http://purl.org/np/RAuK2SpdSrihmtW-VW1AcZGZP1hr4oW30pnWBV-AEakLs
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RAuK2SpdSrihmtW-VW1AcZGZP1hr4oW30pnWBV-AEakLs#pubinfo
http://purl.org/np/RAuK2SpdSrihmtW-VW1AcZGZP1hr4oW30pnWBV-AEakLs
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RAuK2SpdSrihmtW-VW1AcZGZP1hr4oW30pnWBV-AEakLs#assertion
http://purl.obolibrary.org/obo/DOID_11199
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RAuK2SpdSrihmtW-VW1AcZGZP1hr4oW30pnWBV-AEakLs#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_11199
http://purl.org/np/RAuK2SpdSrihmtW-VW1AcZGZP1hr4oW30pnWBV-AEakLs#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RAuK2SpdSrihmtW-VW1AcZGZP1hr4oW30pnWBV-AEakLs#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB00136
http://purl.org/np/RAuK2SpdSrihmtW-VW1AcZGZP1hr4oW30pnWBV-AEakLs#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RAuK2SpdSrihmtW-VW1AcZGZP1hr4oW30pnWBV-AEakLs#association
http://www.w3.org/2000/01/rdf-schema#label
predialysis patients calcitriol oral solution is indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure ccr 15 to 55 ml min not yet on dialysis in children the creatinine clearance value must be corrected for a surface area of 1 73 square meters a serum ipth level of 1 pg ml is strongly suggestive of secondary hyperparathyroidism dialysis patients calcitriol oral solution is indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis in these patients calcitriol oral solution administration enhances calcium absorption reduces serum alkaline phosphatase levels and may reduce elevated parathyroid hormone levels and the histological manifestations of osteitis fibrosa cystica and defective mineralization hypoparathyroidism patients calcitriol oral solution is also indicated in the management of hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidism idiopathic hypoparathyroidism and pseudohypoparathyroidism
http://purl.org/np/RAuK2SpdSrihmtW-VW1AcZGZP1hr4oW30pnWBV-AEakLs#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RAuK2SpdSrihmtW-VW1AcZGZP1hr4oW30pnWBV-AEakLs#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RAuK2SpdSrihmtW-VW1AcZGZP1hr4oW30pnWBV-AEakLs#association
https://w3id.org/biolink/vocab/relation
https://w3id.org/um/neurodkg/SymptomaticReliefIndication
https://identifiers.org/drugbank:DB00136
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RAuK2SpdSrihmtW-VW1AcZGZP1hr4oW30pnWBV-AEakLs#provenance
http://purl.org/np/RAuK2SpdSrihmtW-VW1AcZGZP1hr4oW30pnWBV-AEakLs#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAuK2SpdSrihmtW-VW1AcZGZP1hr4oW30pnWBV-AEakLs#pubinfo
http://purl.org/np/RAuK2SpdSrihmtW-VW1AcZGZP1hr4oW30pnWBV-AEakLs#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RAuK2SpdSrihmtW-VW1AcZGZP1hr4oW30pnWBV-AEakLs#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RAuK2SpdSrihmtW-VW1AcZGZP1hr4oW30pnWBV-AEakLs#sig
http://purl.org/nanopub/x/hasSignature
Qa9CCDGxt0tiC2GborRIpO8j1+HdNNlOz0WOl14qSvVku8CujA9oWO4BVs/9+3hLEbIiIQ4+pG1gaprTtwAPdehJN3fb890+h1G3w/twuK/i85W/Len3Z2x5py6S9PM8OxIHYXWyOC9CGlIKvGZ395GB8k67y/oZYs9Lh6tAdNc=
http://purl.org/np/RAuK2SpdSrihmtW-VW1AcZGZP1hr4oW30pnWBV-AEakLs#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RAuK2SpdSrihmtW-VW1AcZGZP1hr4oW30pnWBV-AEakLs
http://purl.org/np/RAuK2SpdSrihmtW-VW1AcZGZP1hr4oW30pnWBV-AEakLs
http://purl.org/dc/terms/created
2021-07-03T12:15:58.917+02:00
http://purl.org/np/RAuK2SpdSrihmtW-VW1AcZGZP1hr4oW30pnWBV-AEakLs
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAuK2SpdSrihmtW-VW1AcZGZP1hr4oW30pnWBV-AEakLs
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RAuK2SpdSrihmtW-VW1AcZGZP1hr4oW30pnWBV-AEakLs
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RAuK2SpdSrihmtW-VW1AcZGZP1hr4oW30pnWBV-AEakLs
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs